Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 4/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.33 |
| ▸ | RORB | Q92753 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | ICMT | O60725 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17974907 | 0.84 | PTPN5 (0.58) | PTPN5HTR7PDK2PGRAR | |
| SCHEMBL17974911 | 0.72 | HTR7 (0.40) | PTPN5HTR7PDK2ARRORB | |
| SCHEMBL20724250 | 0.70 | PTPN5 (0.37) | PTPN5HTR7FFAR1PTGER4NR1H2 | |
| SCHEMBL17974916 | 0.66 | MAOB (0.41) | PDK2PGRARFFAR1AKR1C3 | |
| SCHEMBL1133453 | 0.65 | PTPN5 (0.69) | PTPN5HTR7PDK2PGRAR | |
| SCHEMBL29629090 | 0.61 | HTR7 (0.53) | PTPN5HTR7 | |
| SCHEMBL17974909 | 0.61 | NR1H2 (0.44) | NR1H2 | |
| SCHEMBL17974819 | 0.61 | AKT1 (0.40) | PDK2 | |
| SCHEMBL17974974 | 0.60 | TSHR (0.52) | NR1H2 | |
| SCHEMBL17974910 | 0.60 | MKNK1 (0.44) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | TAF1, TAF1L, TAF1B | PTPN5 3893/4885HTR7 4395/4885PDK2 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.